Navigation Links
HUYA BIOSCIENCE INTERNATIONAL ENGAGES IN PARTNERSHIP WITH LIAONING (BENXI) BIO-PHARMACEUTICAL INDUSTRY BASE
Date:7/8/2011

SAN DIEGO, July 8, 2011 /PRNewswire/ -- HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovations, today announced a strategic partnership with the Liaoning (Benxi) Bio-pharmaceutical Industry Base. The collaboration agreement will combine both parties' strength in aiding the advancement of China's drug innovation platform.

HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing clinical stage compounds from the country, utilizing its expertise to advance these compounds for global markets.

Liaoning (Benxi) Bio-pharmaceutical Industry Base is the third national biomedical industry base approved by the National Ministry of Science and Technology. Located between Benxi and Shenyang, Liaoning (Benxi) Bio-pharmaceutical Industry Base is now the northeast pharmaceutical center and has attracted both domestic and foreign pharmaceutical companies and research institutions to assemble at this base, including Shenyang Pharmaceutical University, Liaoning Analytical Science Research Institute, and Liaoning TCM Research Institute.

Under the agreement, Liaoning (Benxi) Bio-pharmaceutical Industry Base and HUYA will collaborate to promote new drug development. HUYA will have the first opportunity to provide assistance in evaluating research and development projects conducted by pharmaceutical enterprises residing in Liaoning (Benxi) Bio-pharmaceutical Industry Base. HUYA will also be able to globalize select programs from Liaoning (Benxi) Bio-pharmaceutical Industry Base through HUYA's innovative co-development model and worldwide pharmaceutical partners.

"It's a great honor to form the partnership with Liaoning (Benxi) Bio-pharmaceutical Industry Base," said Clement Gingras, HUYA's CTO and COO, China. "Together, we will help promote the acceleration and development of China's emerging biopharmaceutical industry."

Xiaofan Zhang, Vice Director of Liaoning (Benxi) Bio-pharmaceutical Industry Base, commented, "Liaoning (Benxi) Bio-pharmaceutical Industry is committed to becoming the 'pharmaceutical valley' in northern China; with HUYA's knowledge and capacity in international drug development, Liaoning (Benxi) Bio-pharmaceutical Industry Base hopes to solidify its position as a leading medical and pharmaceutical base in China."

ABOUT HUYA BIOSCIENCE INTERNATIONAL

HUYA is the leader in global pharmaceutical co-development with Chinese partners. With seven offices strategically located in China, the most comprehensive Chinese compound portfolio, and a rapidly growing number of exclusive agreements with premier Chinese research and development organizations, HUYA is uniquely positioned to identify and license novel Chinese compounds. HUYA offers Western pharmaceutical companies efficient access to innovative therapeutic opportunities and helps to reduce deal-making complexity in China. The company has become a champion of guiding China's biomedical innovations to the worldwide marketplace. HUYA has joint headquarter offices in San Diego, CA, USA and Shanghai, China. Additional information about the company is available at www.huyabio.com.

ABOUT LIAONING (BENXI) BIO-PHARMACEUTICAL INDUSTRY BASE

Liaoning (Benxi) Bio-pharmaceutical Industry Base is situated in between Benxi and the Liaoning provincial capital, Shenyang. It spans an area of 205 square km. Up to date, 264 enterprises have invested a total of 73.9 billion RMB ($11.4 billion) in the pharmaceutical base, with accumulated production capacity of 98 billion RMB ($15.1 billion). In 2010, with the approval from Ministry of Science and Technology, Liaoning (Benxi) Bio-pharmaceutical Industry Base formally became a national-level high-tech industry base.  For more information, please visit www.benxi.gov.cn  

CONTACT

USA:
Yung-Chih Wang, Ph.D., MBA
Vice President, Corporate Development, China
HUYA Bioscience International
+1.858.798.8800
ywang@huyabio.com

China:
Qing (Vicky) Xia, MS, MBA
Senior Business Development Manager
HUYA Bioscience International
+86.21.51323312
vxia@huyabio.com


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Coronado Biosciences Closes $25.8M in Series C Financing
2. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
3. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
4. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
5. BIOSCIENCE EAST, the Life Sciences Industry Map, Highlighting Global Leaders in Healthcare Innovation, Kicks Off 5th Edition
6. Generex Announces Intention to Dividend a Portion of Anticipated Amarantus BioSciences Shares to Its Shareholders upon a Reverse Stock Split
7. Neurocrine Biosciences to Present at the Jefferies 2011 Global Healthcare Conference
8. Generex in Agreement to License RapidMist™ Technology for $10 Million to Amarantus BioSciences for Use With Its Proprietary MANF Proteins
9. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
10. Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics®
11. BD Biosciences Launches New Cell Analyzer to Streamline Research Workflow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... -- The leader in accelerated orthodontics, OrthoAccel ® Technologies, ... Manal Ibrahim , Kenji Ojima , ... featured microlecture presenters at the AcceleDent ® booth ... Annual Session, April 21-25, 2017. Orthodontists and their staff ... 11:20 a.m. On the opening morning of AAO exhibitions, ...
(Date:3/29/2017)... , March 29, 2017  Maxor National Pharmacy Services, ... that it has named Leah Bailey as ... divisions of the company. With more than ... previous 8 years focused on health care, Bailey joins ... tenure at Prime, Bailey advised the PBM, Specialty, and ...
(Date:3/29/2017)... JOSE, Calif. , March 29, 2017  Designers ... now significantly reduce solution size by 50% and extend ... Q ) power management integrated circuit (PMIC) from Maxim ... wearable PMIC supports a low input voltage of just ... Zinc Air and Silver Oxide, as well as the ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Patients interested in receiving ... from Dr. Jamie Cameron, with or without a referral. The FASTBRACES system is ... Depending on each patient’s case, treatment with the FASTBRACES system could be completed ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... (GRMA) is growing as it continues developing an ANSI-approved, consensus-based American National ... organization, which plans to publish the first ANSI-approved GMP standard for dietary ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... for documenting and diagramming network and data center assets and audio-video devices has ... can request new equipment shapes for free and download shapes and stencils from ...
(Date:3/29/2017)... ... March 29, 2017 , ... An ... braces. "The rubber bands used in conjunction with my braces always rubbed against ... design a way to prevent this problem." The O.B.S. was the result of ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... many scientific laboratories. The assembly protocols involve many repetitive steps and often scientists ... automation, which enables the high-throughput needed, and results in a lower error rate ...
Breaking Medicine News(10 mins):